Hiroki Kubota
Yatomi, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.
Journal: Cancer medicine
Published: January 14, 2026
A Rare Case of Clear Cell Carcinoma Associated With Papillary Cystadenoma Originating in the Epididymis.
Journal: IJU case reports
Published: October 21, 2025
Original Training for Laparoscopic Surgery by Making an Origami Paper Crane.
Journal: Cureus
Published: June 10, 2024
Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: November 19, 2022
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.
Journal: Scientific reports
Published: October 12, 2022
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Journal: International journal of clinical oncology
Published: July 30, 2021
Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma.
Journal: In vivo (Athens, Greece)
Published: March 21, 2021
Improvement in early urinary continence recovery after robotic-assisted radical prostatectomy based on postoperative pelvic anatomic features: a retrospective review.
Journal: BMC urology
Published: May 22, 2018
Last Updated: 09/26/2026